PERK Protein (AA 665-764) (GST tag)
-
- Antigène Voir toutes PERK (EIF2AK3) Protéines
- PERK (EIF2AK3) (Eukaryotic Translation Initiation Factor 2-alpha Kinase 3 (EIF2AK3))
- Type de proteíne
- Recombinant
- Attributs du protein
- AA 665-764
-
Origine
- Humain
-
Source
- Wheat germ
- Purification/Conjugué
- Cette PERK protéine est marqué à la GST tag.
- Application
- Western Blotting (WB), Antibody Array (AA), Affinity Purification (AP), ELISA
- Fonction
- EIF2AK3 (Human) Recombinant Protein (Q01)
- Séquence
- KWQEKMDEIW LKDESTDWPL SSPSPMDAPS VKIRRMDPFS TKEHIEIIAP SPQRSRSFSV GISCDQTSSS ESQFSPLEFS GMDHEDISES VDAAYNLQDS
- Attributs du produit
- Human EIF2AK3 partial ORF ( NP_002437, 665 a.a. - 764 a.a.) recombinant protein with GST-tag at N-terminal.
- Purification
- in vitro wheat germ expression system
-
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Commentaires
-
Preparation method: in vitro, wheat germ expression system
Product Quality tested by: 12.5% SDS-PAGE Stained with Coomassie Blue. - Restrictions
- For Research Use only
-
- Buffer
- 50 mM Tris-HCI, 10 mM reduced Glutathione, pH =8.0 in the elution buffer.
- Conseil sur la manipulation
- Aliquot to avoid repeated freezing and thawing.
- Stock
- -80 °C
- Stockage commentaire
- Best use within three months from the date of receipt of this protein.
-
- Antigène
- PERK (EIF2AK3) (Eukaryotic Translation Initiation Factor 2-alpha Kinase 3 (EIF2AK3))
- Autre désignation
- EIF2AK3 (EIF2AK3 Produits)
- Synonymes
- EIF2AK3 Protein, AI427929 Protein, Pek Protein, Perk Protein, PEK Protein, PERK Protein, WRS Protein, eukaryotic translation initiation factor 2 alpha kinase 3 Protein, EIF2AK3 Protein, Eif2ak3 Protein
- Sujet
-
Full Gene Name: eukaryotic translation initiation factor 2-alpha kinase 3
Synonyms: DKFZp781H1925,HRI,PEK,PERK,WRS - ID gène
- 9451
- NCBI Accession
- NM_004836
- Pathways
- Hormone Transport, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Unfolded Protein Response
-